353 related articles for article (PubMed ID: 29548847)
1. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age.
van Bergen JMG; Li X; Quevenco FC; Gietl AF; Treyer V; Meyer R; Buck A; Kaufmann PA; Nitsch RM; van Zijl PCM; Hock C; Unschuld PG
Neuroimage; 2018 Jul; 174():308-316. PubMed ID: 29548847
[TBL] [Abstract][Full Text] [Related]
2. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Susceptibility Mapping of Brain Iron and β-Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults.
Chen L; Soldan A; Oishi K; Faria A; Zhu Y; Albert M; van Zijl PCM; Li X
Radiology; 2021 Feb; 298(2):353-362. PubMed ID: 33231528
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
5. Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old.
van Bergen JMG; Li X; Quevenco FC; Gietl AF; Treyer V; Leh SE; Meyer R; Buck A; Kaufmann PA; Nitsch RM; van Zijl PCM; Hock C; Unschuld PG
Neurobiol Aging; 2018 Apr; 64():68-75. PubMed ID: 29351872
[TBL] [Abstract][Full Text] [Related]
6. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
7. Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline.
Ayton S; Fazlollahi A; Bourgeat P; Raniga P; Ng A; Lim YY; Diouf I; Farquharson S; Fripp J; Ames D; Doecke J; Desmond P; Ordidge R; Masters CL; Rowe CC; Maruff P; Villemagne VL; ; Salvado O; Bush AI
Brain; 2017 Aug; 140(8):2112-2119. PubMed ID: 28899019
[TBL] [Abstract][Full Text] [Related]
8. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
[TBL] [Abstract][Full Text] [Related]
9. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
10. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Susceptibility Mapping of Amyloid-β Aggregates in Alzheimer's Disease with 7T MR.
Tiepolt S; Schäfer A; Rullmann M; Roggenhofer E; ; Gertz HJ; Schroeter ML; Patt M; Bazin PL; Jochimsen TH; Turner R; Sabri O; Barthel H
J Alzheimers Dis; 2018; 64(2):393-404. PubMed ID: 29865069
[TBL] [Abstract][Full Text] [Related]
12. Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls - A hybrid PET/MRI study.
Tiepolt S; Rullmann M; Jochimsen TH; Gertz HJ; Schroeter ML; Patt M; Sabri O; Barthel H
Eur J Radiol; 2020 Oct; 131():109243. PubMed ID: 32916411
[TBL] [Abstract][Full Text] [Related]
13. Estimation of amyloid distribution by [
Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
[TBL] [Abstract][Full Text] [Related]
14. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
15. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
16. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
17. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
19. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
[TBL] [Abstract][Full Text] [Related]
20. Is there a difference in regional read [
Farrar G; Molinuevo JL; Zanette M
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]